SynthesisOncoimmunology2020
Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis.
Synthesis in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- The Effect of Delayed Oncology Surgery on Survival Outcomes for Patients With Gastric Cancer During the COVID-19 Pandemic: Evidence-Based Strategies.Frontiers in oncology · 2022Pooled it
- Early mortality in patients with cancer and COVID-19 infection treated with immunotherapy.BMC cancer · 2025Article
- Factors influencing in-hospital mortality in cancer patients with COVID-19: A retrospective survival analysis.SAGE open medicine · 2024Article
- Cancer, more than a "COVID-19 co-morbidity".Frontiers in oncology · 2023Review
- Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.Vaccine · 2022Review
- pH Sensitive Pluronic Acid/Agarose-Hydrogels as Controlled Drug Delivery Carriers: Design, Characterization and Toxicity Evaluation.Pharmaceutics · 2022Article
- Infection and reinfection with SARS-CoV-2 in cancer patients: A cohort study.Experimental and therapeutic medicine · 2022Article
- Resolving sticky relationships between platelets and lymphocytes in COVID-19: A role for checkpoint inhibitors?British journal of haematology · 2022Article
- Article
- Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis.Journal of Zhejiang University. Science. B · 2021Article
- ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO).European heart journal supplements : journal of the European Society of Cardiology · 2021Article
- [COVID-19 severity and outcomes in patients with cancer: a matched cohort study].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.Cancer immunology research · 2021Article
- New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era.Journal of clinical medicine · 2021Review
- Viral Infection and Lung Cancer Immunotherapy.Frontiers in oncology · 2021Review
- The Sum of Fears in Cancer Patients Inside the Context of the COVID-19.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study was designed to investigate whether COVID-19 patients with recently received immunotherapy or other anti-cancer treatments had more severe symptoms and higher mortality. Methods: A literature search was performed using the electronic platforms to obtain relevant research studies published up to June 28, 2020. Odds ratio (OR) and 95% confidence intervals (CI) of research endpoints in each study were calculated and merged. Statistical analyses were performed with Stata 12.0 (Stata Corp LP, College Station, TX). Results: A total of 17 studies comprising 3581 cancer patients with COVID-19 were included in this meta-analysis. SARS-CoV-2-infected cancer patients who recently received anti-cancer treatment did not observe a higher risk of exacerbation and mortality (All Conclusion: Cancer patients recently under anti-cancer treatment before diagnosed with COVID-19, including surgery, targeted therapy, immunotherapy, and radiotherapy, were not associated with increased risk of exacerbation and mortality. Chemotherapy within 28 d increased the risk of mortality, and chemotherapy was not associated with increased risk of severe COVID-19. The role of anti-cancer therapy in cancer patients with COVID-19 still needs further exploration, especially chemotherapy and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.